American Society of HematologyASH Annual Meeting: Does High-Dose Methotrexate Protect the CNS in High-Risk DLBCL?
The possible answer was presented during the 2020 ASH Annual Meeting, bringing into question whether current recommendations for prophylactic intravenous high-dose methotrexate — the most widely adopted method for CNS relapse prevention — are appropriate for all patients at high risk of a CNS relapse.